CURE RARE DISEASE INC

CURE RARE DISEASE INC is a research-focused entity dedicated to advancing therapeutic development for rare genetic disorders, with an emphasis on translational science and patient-centered innovation. The company’s core capabilities center on preclinical and clinical-stage drug discovery, gene therapy design, and precision medicine platforms tailored to ultra-orphan conditions. Technical expertise includes molecular diagnostics, vector engineering, natural history studies, and regulatory strategy development for orphan drug designation under the FDORA framework. Key differentiators lie in their integrated approach to connecting patient advocacy networks with academic and clinical research partners to accelerate pathway validation and trial recruitment for conditions with limited commercial incentive. Their work prioritizes scalable, biomarker-driven interventions and leverages real-world evidence to support regulatory submissions. No award history is available to infer specific agency engagements or contract patterns. Consequently, there is no demonstrable track record of direct federal contracting activity or institutional partnerships with government entities such as NIH, FDA, or CDC. The company operates within the biotechnology and medical research sector, though no NAICS codes are available to classify its primary market activity. In practice, this suggests a focus on early-stage therapeutic development rather than large-scale government procurement, positioning the organization as a niche innovator in rare disease research rather than a traditional federal contractor. CURE RARE DISEASE INC is structured as an 8H entity, indicating a small business classification under federal guidelines, and is headquartered in Woodbridge, Connecticut. The company holds no government certifications beyond its 8H status and has not been documented as holding additional accreditations such as ISO, CMMI, or HIPAA compliance. Its geographic presence is limited to its primary location, with no evidence of federal contract distribution or multi-site operational footprint.